BACKGROUND: @entity8999 (BKPyV) @entity646 / @entity8 and reduction in immunosuppression following @entity646 may increase the risk of alloimmune activation and allograft rejection. This study investigates the impact of @entity646 on de novo donor anti-human @entity4107 (HLA)-specific antibodies (dnDSA). @entity1 AND METHODS: All primary renal transplants at East Carolina University from March 1999 to December 2010, with at least 1 post-transplant BKPyV viral load testing, were analyzed. @entity1 were negative for anti-HLA antibodies to donor antigens (tested via single antigen beads) at transplantation and at first BKPyV testing. RESULTS: Nineteen of 174 @entity1 (11%) tested positive for @entity646 . Within 24  months of @entity646 detection, 79% of BKPyV-viremic @entity1 developed dnDSA. Only 20% of @entity646 -persistent cases, compared to 86% of @entity646 -resolved cases, developed dnDSA (P  =  0.03). Poor allograft survival was evident in @entity646 -persistent @entity1 (60% failure by 2  years post BKPyV diagnosis) and in @entity646 -resolved @entity1 with dnDSA (5-year post BKPyV diagnosis allograft survival of 48%). CONCLUSIONS: Post-transplant @entity646 and preemptive immunosuppression reduction is associated with high rates of dnDSA. When preemptively treating @entity646 , dnDSA should be monitored to prevent allograft consequences.

Onset and progression of de novo donor-specific anti-human XXXX antibodies after @entity8999 and preemptive immunosuppression reduction.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS'] @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy'] @entity646 :: ('MESH:D014766', 'Disease') :: ['BKPyV viremia', 'viremia'] @entity8999 :: ('10629', 'Species') :: ['BK polyomavirus'] @entity4107 :: ('3126', 'Gene') :: ['leukocyte antigen']
@entity4107 :: (3126,Gene) :: ['leukocyte antigen']
